Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells

Neuro-Oncology

Volumn 12, Issue 4, 2010, Pages 389-400

  Kim, Ella L ^a   Wüstenberg, Robin ^b   Rübsam, Anne ^a   Schmitz Salue, Christoph ^a   Warnecke, Gabriele ^c   Bücker, Eva Maria ^a   Pettkus, Nadine ^a   Speidel, Daniel ^d   Rohde, Veit ^a   Schulz Schaeffer, Walter ^a   Deppert, Wolfgang ^c   Giese, Alf ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^d CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Apoptosis; Chloroquine; Glioma; p53; Transcription

Indexed keywords

CASPASE 3; CHLOROQUINE; DNA; PROTEIN P53; SMALL INTERFERING RNA; ANTIMALARIAL AGENT; MESSENGER RNA;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS INDEX; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; CELL PROLIFERATION; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; GLIOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIMALARIALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL PROLIFERATION; CHLOROQUINE; GLIOMA; HUMANS; MICE; MICE, NUDE; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954653486     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop046     Document Type: Article

References (52)

1. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006;11:152-164.
2. Lonardi S, Tosoni A, Brandes AA. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev. 2005;31: 79-89.
3. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006:24: 1253-1265.
4. Salhia B, Tran NL, Symons M, Winkles JA, Rutka JT, Berens ME. Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn. 2006;6:613-626.
5. Terzis AJ, Niclou SP, Rajcevic U, Danzeisen C, Bjerkvig R. Cell therapies for glioblastoma. Expert Opin Biol Ther. 2006;6:739-749.
6. Naumann U, Kügler S,Wolburg H, et al. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res. 2001;61:5833-5842.
7. Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol. 2003;65:237-246.
8. Cerrato JA, Khan T, Koul D, et al. Differential activation of the Fas/ CD95 pathway by Ad-p53 in human gliomas. Int J Oncol. 2004;24: 409-417.
9. Nakamizo A, Amano T, Zhang W, et al. Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis. Neuro Oncol. 2008;10: 275-291.
10. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirusmediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21:2508-2518.
11. Vousden KH. Outcomes of p53 activation-spoilt for choice. J Cell Sci. 2006;119:5015-5020.
12. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120:7-10.
13. Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck. 2007;29: 272-284.
14. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892-6899.
15. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453.
16. Steinbach JP, Weller M. Apoptosis in gliomas: molecular mechanisms and therapeutic implications. J Neurooncol. 2004;70:247-256.
17. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 2007;26:1306-1316.
18. Paul M, Gafter-Gvili A, Fraser A, Leibovici L. The anti-cancer effects of quinolone antibiotics? Eur J Clin Microbiol Infect Dis. 2007;26: 825-831.
19. Radl S. From chloroquine to antineoplastic drugs? The story of antibacterial quinolones. Arch Pharm (Weinheim). 1996;329:115-119. (Pubitemid 26127729)
20. Savarino A, Lucia MB, Giordano F, Cauda R. Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol. 2006;7: 792-793.
21. Mitscher LA. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev. 2005;105:559-592.
22. Boya P, Gonzalez-Polo RA, Poncet D, et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene. 2003;22:3927-3936.
23. Boya P, Gonzá lez-Polo RA, Casares N, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 2005;25:1025-1040.
24. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007;117:326-336.
25. Shacka JJ, Klocke BJ, Shibata M, et al. 1 inhibits chloroquine-induced death of cerebellar granule neurons. Mol Pharmacol. 2006;69: 1125-1136.
26. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest. 2008;118: 79-88.
27. Fan C, Wang W, Zhao B, Zhang S, Miao J. Chloroquine inhibits cell growth and induces cell death in A549 lung cancer cells. Bioorg Med Chem. 2006;14:3218-3222.
28. Gurova KV, Hill JE, Guo C, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA. 2005;102: 17448-17453.
29. Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus. 2003;14:e3.
30. Briceno E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol. 2007;67:388-391.
31. Kim EL, Yoshizato K, Kluwe L, et al. Comparative assessment of the functional p53 status in glioma cells. Anticancer Res. 2005;25: 213-224.
32. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,50,6,60- tetrachloro-1,10,3, 30-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun. 1993;197:40-45.
33. Brockmann MA, Westphal M, Lamszus K. Improved method for the intracerebral engraftment of tumour cells and intratumoural treatment using a guide screw system in mice. Acta Neurochir (Wien). 2003;145:777-781; discussion 781.
34. Zaidi AU, McDonough JS, Klocke BJ, et al. Chloroquine-induced neuronal cell death is p53 and Bcl-2 family-dependent but caspase-independent. J Neuropathol Exp Neurol. 2001;60: 937-945.
35. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res. 2007;13: 7271-7279.
36. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ. 2003;10:400-403.
37. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol. 2003;15: 164-171.
38. Loehberg CR, Thompson T, Kastan MB, et al. Ataxia telangiectasiamutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res. 2007;67: 12026-12033.
39. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 2001;268:2764-2772.
40. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263-269.
41. Finkelstein SD, Black P, Nowak TP, Hand CM, Christensen S, Finch PW. Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. Neurosurgery. 1994;34:136-143.
42. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol. 2005;17: 631-636.
43. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760.
44. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res. 2007;67:11886-11895.
45. Xu GW, Mymryk JS, Cairncross JG. Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. Int J Cancer. 2005;116:187-192.
46. Xu GW, Nutt CL, Zlatescu MC, Keeney M, Chin-Yee I, Cairncross JG. Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis (2-chloroethyl)-1-nitrosourea. Cancer Res. 2001;61:4155-4159.
47. Xu GW, Mymryk JS, Cairncross JG. Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. J Neurooncol. 2005;74:141-149.
48. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499-506.
49. Kim E, Deppert W. The versatile interactions of p53 with DNA: when flexibility serves specificity. Cell Death Differ. 2006;13: 885-889.
50. Cheng J, Zeidan R, Mishra S, et al. Structure-function correlation of chloroquine and analogues as transgene expression enhancers in nonviral gene delivery. J Med Chem. 2006;49:6522-6531.
51. Levraut J, Iwase H, Shao ZH, Vanden Hoek TL, Schumacker PT. Cell death during ischemia: relationship to mitochondrial depolarization and ROS generation. Am J Physiol Heart Circ Physiol. 2003;284:H549-H558.
52. Krohn AJ, Wahlbrink T, Prehn JH. Mitochondrial depolarization is not required for neuronal apoptosis. J Neurosci. 1999;19:7394-7404.